MedTrace Logo

Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III

NCT00846274 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-02-18

No results posted yet for this study

Summary

To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed

Conditions

  • Healthy

Interventions

BIOLOGICAL

SK Antithrombin III

Sponsors & Collaborators

  • Korea University Anam Hospital

    collaborator OTHER

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ji Young Park, MD,PhD · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846274 on ClinicalTrials.gov